In mice, harmful T cells attacking the brain in tau-driven neurodegeneration were activated in lymph nodes — and blocking that step preserved memory, all without a drug crossing into the brain.
Ionis’s Zanvastro, an antisense drug that dials down a toxic protein, stabilized walking in patients with the ultra-rare, progressive neurological disorder — which until now had no disease-modifying therapy.
The deal licenses HMPL-A830, an antibody-delivered therapy designed to shut down both EGFR and KRAS — a driver mutation in many colorectal, lung and pancreatic cancers.
Surging demand for hormone therapy has outstripped supply of the transdermal patches, and the FDA is pressing manufacturers to ramp up production.
Two people who received gene-edited pig kidneys went on to receive human kidney transplants without antibody complications — evidence that xenotransplants could serve as a bridge while patients wait.
After a bruising regulatory saga, the company submitted AMT-130 — a one-time, brain-delivered gene therapy that slowed disease progression over three years — for accelerated approval.
The company helps patients steer through cancer care — and is now building a broader oncology group backed by Humana, CVS and JPMorgan’s Morgan Health.
The GLP-1 drug behind Ozempic and Wegovy lengthened lifespan and improved muscle, memory and inflammation in old mice — and the benefits weren’t explained by calorie cutting alone.
Harvard researchers converted human pancreatic duct cells into insulin-making “beta-like” cells by disabling a single gene — a potential new route to replacing what diabetes destroys.
In a Phase 3 trial, pulmonary-artery denervation cut clinical worsening roughly in half for patients whose heart failure had driven up pressure in the lungs’ arteries.
There’s no approved drug for celiac disease — only a strict gluten-free diet. Teva’s experimental TEV-408 significantly reduced gluten-triggered intestinal damage in a mid-stage study.
The deal buys rights to an early-stage “tri-specific” antibody built to hit B cells — drivers of many autoimmune conditions — from multiple angles at once.